Clostridium difficile Infection Market to Show Immense Growth at a CAGR of 12.5% During the Study Period (2019-2032) | DelveInsight

The Clostridium difficile infection market is anticipated to surge owing to the launch of emerging therapies. The potential emerging treatment expected to launch in the forecast period includes both preventive and therapeutic agents. Some of them are PF-06425090 (Pfizer's vaccine), CP101 (Finch Therapeutics), VE303 (Vedanta Biosciences), NTCD-M3 (Destiny Pharma), and others

LAS VEGAS, Dec. 14, 2022 /PRNewswire/ -- DelveInsight's Clostridium difficile Infection Market Insights report includes a comprehensive understanding of current treatment practices, Clostridium difficile infection emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Takeaways from the Clostridium difficile Infection Market Report

• As per DelveInsight analysis, the Clostridium difficile infection market size in the 7MM was approximately USD 413 million in 2021.
• According to the estimates based on DelveInsight analysis, the total Clostridium difficile infection incident cases in the 7MM were approximately 668K in 2021. 
• Leading Clostridium difficile infection companies such as Pfizer, Valneva, GlaxoSmithKline, Summit Therapeutics, MGB Biopharma, Acurx Pharmaceuticals, Da Volterra, Synthetic Biologics, Deinove, Oragenics, XBiotech, Crestone, MicroPharm Ltd., SAb Biotherapeutics, Seres Therapeutics, Nestlé Health Science, Finch Therapeutics, Destiny Pharma, Vedanta Biosciences, Mikrobiomik Healthcare, Lumen Bioscience, Adiso Therapeutics, Recursion Pharmaceuticals, and others are developing novel Clostridium difficile infection drugs that can be available in the Clostridium difficile infection market in the upcoming years.
• The Clostridium difficile infection preventive and therapeutic agents in the pipeline include PF-06425090, VLA84, GSK2904545A, Ridinilazole, MGB-BP-3, Ibezapolstat, DAV132, SYN-004 (ribaxamase), DNV3837, OG716, Research programme: C. difficile Monoclonal Antibody, CRS3123, OraCAb, SAB-195, SER-109, CP101, NTCD-M3, VE303, MBK-01, LMN-201, ADS024, and others.
• The increase in Clostridium difficile infection market size is a direct consequence of a robust pipeline and increasing incidence of Clostridium difficile infection in the 7MM.
• In November 2022, Ferring Pharmaceuticals announced that the FDA had approved REBYOTA® (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.
• In November 2022, Ferring Pharmaceuticals announced the publication of its pivotal Phase III PUNCHTM CD3 clinical trial data in the journal Drugs, in which a single dose of RBX2660 outperformed placebo in a Bayesian analysis model to reduce the recurrence of Clostridioides difficile infection (CDI) after standard-of-care antibiotic treatment.
• In October 2022, Summit Therapeutics shared the results from its Ri-CoDIFy Phase III clinical trial through an oral abstract presentation at IDWeek 2022; however, the statement provided no update on its plans for ridinilazole.
• In September 2022, the VRBPAC of the US FDA reviewed the data supporting the BLA for RBX2660 and issued a positive vote for REBYOTA (RBX2660). The US FDA has granted FTD, BTD, and ODD to REBYOTA (RBX2660) for treating recurrent Clostridium difficile infection.
• In March 2022, Pfizer announced results from its pivotal Phase III CLOVER trial, evaluating the vaccine candidate, PF-06425090, to prevent Clostridium difficile infection.

Discover which therapies are expected to grab the major Clostridium difficile infection market share @Clostridium difficile Infection Market Report

Clostridium difficile Infection Overview

Clostridium difficile infection is a widespread nosocomial and community-acquired infection that causes diarrhea and colitis. It is caused by gram-positive, anaerobic, spore-forming C. difficile bacteria and accounts for approximately 500,000 infections in the United States annually. Antibiotic exposure, a weakened immune system, and other illnesses disrupt the microbiota, creating an environment favorable for C. difficile spore germination and vegetative cell outgrowth, resulting in overgrowth that would otherwise not be possible in healthy gut microbiota.

The clinical Clostridium difficile infection symptoms are diverse, ranging from mild diarrhea to fulminant colitis, and are accompanied by complications such as toxic megacolon, bowel perforation, sepsis, and death. The detection of toxigenic C. difficile in the stool and colonic histopathology is the gold standard for CDI. Glutamate dehydrogenase (GDH), Toxin enzyme immunoassay (EIA), and Toxin B polymerase chain reaction (PCR) are the most commonly used stool tests.

Clostridium difficile Infection Epidemiology Segmentation

DelveInsight estimates that there were approximately 668K incident cases of Clostridium difficile infection in the 7MM in 2021.

Among the 7MM countries, the US had the highest number of C. difficile infection incident cases in 2021.

The Clostridium difficile infection market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Incident Cases 
• Gender-specific Incident Cases 
• Type-specific Incident Cases 
• Age-specific Incident Cases
• Severity-specific Incident Cases 

Download the report to understand which factors are driving Clostridium difficile infection epidemiology trends @Clostridium difficile Infection Epidemiological Insights

Clostridium difficile Infection Treatment Market 

The current treatment regimen for Clostridium difficile infection is restrictive and difficult due to the high recurrence rates, with most broad-spectrum antibiotics such as clindamycin, cephalosporins, quinolones, and penicillins increasing the risk of Clostridium difficile infection because they deplete gut microbiota, creating an environment conducive to C. difficile multiplication. On the other hand, Tetracyclines and aminoglycosides are still effective against Clostridium difficile infection.

Most Clostridium difficile infection treatment guidelines recommend vancomycin, fidaxomicin, and metronidazole as the antibiotics of choice for various lines of therapy. However, because metronidazole's pharmacokinetics for intestinal infections are inconsistent, vancomycin or fidaxomicin are preferred options for all clinically significant cases of Clostridium difficile infection. 

The current recommended duration of antimicrobial therapy for primary Clostridium difficile infection is 10-14 days, but there is a significant therapeutic conundrum because recovery requires restoration of gut microbiota diversity; however, prolonged antibiotic use disrupts intestinal flora. As a result, probiotic therapy following standard antibiotics may be used to avoid recurrence and restore microbiota, or low-dose antibiotics may be given intermittently to reduce the likelihood of recurrence. The US FDA approved bezlotoxumab, an antitoxin antibody, to prevent recurrent Clostridium difficile infection in adults at high risk of recurrence.

Although antibiotic resistance rates have increased in the last decade, the efficacy of currently recommended Clostridium difficile infection treatments has decreased. The emerging Clostridium difficile infection treatment landscape is robust, with multiple trials for novel targeted antibiotics, vaccines, and regimens to restore intestinal microbiota and provide the much-needed palliative cure currently underway.

To know more about Clostridium difficile infection treatment options, visit @Clostridium difficile Infection Treatment & Management

Clostridium difficile Infection Emerging Vaccines and Key Companies

• PF-06425090: Pfizer
• VLA84: Valneva
• GSK2904545A: GlaxoSmithKline

Emerging Agents for Acute Treatment of Clostridium difficile Infection and Key Companies

• Ridinilazole: Summit Therapeutics
• MGB-BP-3: MGB Biopharma
• Ibezapolstat: Acurx Pharmaceuticals
• DAV132: Da Volterra
• SYN-004 (ribaxamase): Synthetic Biologics
• DNV3837: Deinove
• OG716: Oragenics
• Research programme: C. difficile Monoclonal Antibody: XBiotech

Emerging Agents for Acute Treatment of Clostridium difficile Infection and Prevention/Reduction of Recurrence and Key Companies

• CRS3123: Crestone
• OraCAb: MicroPharm Ltd.
• SAB-195: SAb Biotherapeutics

Emerging Agents for Prevention/Reduction of Recurrence of Clostridium difficile Infection and Key Companies

• SER-109: Seres Therapeutics/Nestlé Health Science
• CP101: Finch Therapeutics
• NTCD-M3: Destiny Pharma
• VE303: Vedanta Biosciences
• MBK-01: Mikrobiomik Healthcare
• LMN-201: Lumen Bioscience
• ADS024: Adiso Therapeutics

Learn more about the drugs used to treat Clostridium difficile infection @Drugs for Clostridium difficile Infection Treatment 

Clostridium difficile Infection Market Dynamics

The dynamics of the Clostridium difficile infection market are anticipated to change in the coming years. With C. difficile becoming the most common microbial cause of healthcare-associated infections in hospitals, there is an increased demand for Clostridium difficile infection treatment. As a result of the high prevalence of Clostridium difficile infection, pharmaceutical companies working in the Clostridium difficile infection market have a tremendous opportunity to develop vaccines to prevent initial Clostridium difficile infection.

Given the increasing resistance rates to antibiotic therapy as the primary treatment, there is an opportunity to develop nonantibiotic therapeutics to treat or prevent Clostridium difficile infection. Furthermore, the emerging Clostridium difficile infection pipeline includes several novel mid and late-stage therapies that will overcome the limitations of current therapies, positively impacting the Clostridium difficile infection market.

However, certain factors are limiting the growth of the Clostridium difficile infection market. A large cohort is required for vaccine clinical trials, which could significantly delay the clinical development process and eventual release of the Clostridium difficile infection vaccine, which is currently being developed. Moreover, antibiotic therapy is the current standard of care (SoC) for recurrent Clostridium difficile infection, which leads to high recurrence rates because antibiotics do not address the underlying microbiome disruption that causes recurrence.

Furthermore, drug side effects are a source of concern for both patients and clinicians, and they are frequently the reason for the discontinuation of a new drug's development or result in poor patient compliance. Treatment practices vary between centers, and there is significant heterogeneity among country-specific epidemiology studies. Thus, all these factors collectively will hamper the growth of the Clostridium difficile infection market in the coming years.

Scope of the Clostridium difficile Infection Market Report

• Therapeutic Assessment: Clostridium difficile Infection current marketed and emerging therapies
• Clostridium difficile Infection Market Dynamics: Clostridium difficile Infection market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Clostridium difficile Infection Market Access and Reimbursement

Discover more about Clostridium difficile infection antibiotics in development @Clostridium difficile Infection Clinical Trials

Table of Contents

Related Reports

Clostridium difficile Infection Epidemiology Forecast

Clostridium difficile Infection Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the Clostridium difficile infection epidemiology trends.

Clostridium difficile Infection Pipeline

Clostridium difficile Infection Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key Clostridium difficile infection companies, including Crestone, MicroPharm Ltd., SAb Biotherapeutics, Ferring Pharmaceuticals, Seres Therapeutics, Nestlé Health Science, Finch Therapeutics, among others.

Recurrent Clostridioides difficile Infection Pipeline

Recurrent Clostridioides difficile Infection Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key recurrent Clostridioides difficile infection companies such as Vedanta Biosciences, Rebiotix, Takeda, Adiso Therapeutics, among others.

Helicobacter pylori Infection Market

Helicobacter pylori Infection Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key Helicobacter pylori infection companies, including Eisai Co, MerLion Pharmaceuticals, Bayer, RaQualia Pharma, HKinno.N, SCG Cell Therapy, Recce Pharmaceuticals, Infan Industria Quimica Farmaceutica Nacional, among others.

Bacteremia Market

Bacteremia Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key bacteremia companies, including Armata Pharmaceuticals, Contrafect, Basilea Pharmaceutical, among others.

Staphylococcus aureus Bacteremia Market

Staphylococcus aureus Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key Staphylococcus aureus companies, including ContraFect, XBiotech, Genentech, Durata Therapeutics, among others.

Other Trending Reports

Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | CAR-T Pipeline Insight | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Outlook Report | Crows Feet Market Insight | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services 

Contact Us
Shruti Thakur 
[email protected] 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED